[Translation] Comparison of the efficacy and tolerability of fulvestrant 500 mg and 250 mg in postmenopausal women with ER-positive advanced breast cancer who have progressed or relapsed after endocrine therapy

本研究比较氟维司群500mg和250mg用于雌激素受体阳性既往抗雌激素治疗或者芳香化酶抑制剂治疗疾病进展的绝经后晚期乳腺癌的疗效和安全性

[Translation]

This study compared the efficacy and safety of fulvestrant 500 mg and 250 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer who had disease progression on prior anti-estrogen therapy or aromatase inhibitor therapy.

Start Date01 Mar 2011

Sponsor / Collaborator

Vetter Pharma-Fertigung GmbH & Co. KG

[+1]

100 Clinical Results associated with AstraZeneca (Wuxi) Trading Co. Ltd.

0 Patents (Medical) associated with AstraZeneca (Wuxi) Trading Co. Ltd.

Literatures (Medical) associated with AstraZeneca (Wuxi) Trading Co. Ltd.

01 Jul 2020·Current MicrobiologyQ4 · BIOLOGY

Nitratireductor mangrovi sp. nov., a Nitrate-Reducing Bacterium Isolated from Mangrove Soil

Q4 · BIOLOGY

Article

Author: Zhang, Ran ; Xiao, Chuan ; Yan, Cen ; Wu, Min ; Zhao, Zhe ; Nie, Yanfang ; Ye, Yanghui ; Zhang, Jianwei

A Gram-stain-negative, non-motile and short-rod-shaped bacterium, designated as strain SY7^T, was isolated from rhizosphere soil of the mangrove Kandelia obovata of Fugong village, in Zhangzhou, China. The isolate grew at 10-45 °C (optimum 30 °C), pH 6.0-10.0 (optimum pH 7.0) and 0-8% NaCl (optimum 3%, w/v). The 16S rRNA gene sequence and phylogenetic analysis revealed that strain SY7^T located within the radiation of genus Nitratireductor and showed the highest sequence similarity of 97.23% to Nitratireductor pacificus MCCC 1A01024^T. The DNA G+C content was 64.9%. In silico DNA-DNA hybridization and average nucleotide identity values between strain SY7^T with reference strains of N. pacificus MCCC 1A01024^T, N. basaltis KCTC 22119^T and N. aquibiodomus DSM 15645^T were 16.7%, 14.3%, 14.7% and 75.2%, 72.6%, 73.5%, respectively. The major isoprenoid quinone was Q-10. The dominant fatty acids were 11-methyl C_18:1ω7c, iso-C_17:0, C_19:0ω8c cyclo and summed feature 8 (C_18:1ω6c/C_18:1ω7c), a profile that almost matched the other members of the genus Nitratireductor. The predominant polar lipids were phosphatidylcholine, phosphatidylglycerol, phosphatidylethanolamine, diphosphatidylglycerol. On the basis of the phenotypic, phylogenetic and chemotaxonomic analysis, strain SY7^T represents a novel species of the genus Nitratireductor, for which the name Nitratireductor mangrovi sp. nov., is proposed. The type strain is SY7^T (= KCTC 72110^T = MCCC 1K03723^T).

Frontiers in MicrobiologyQ2 · BIOLOGY

Discovery of Three 22-Membered Macrolides by Deciphering the Streamlined Genome of Mangrove-Derived Streptomyces sp. HM190

Q2 · BIOLOGY

ArticleOA

Author: Zhang, Jianwei ; Wu, Min ; Wu, Shihua ; Wang, Jidong ; Mao, Xuming ; Anwar, Nusratgul ; Yan, Cen ; Nie, Yanfang ; Ye, Yanghui ; Zhang, Ran ; Zhao, Zhe

Strain HM190, a moderate halophile, was isolated from rhizosphere soil of the mangrove Kandelia obovata in Fugong village, China. The 16S ribosomal RNA (rRNA) gene sequence and the results of phylogenetic analysis revealed that strain HM190 belonged to the genus Streptomyces and had the highest sequence similarity of 99.79% to Streptomyces heilongjiangensis NEAU-W2^T. The complete genome of strain HM190 comprised 7,762,826 bp in a linear chromosome with 71.97% G + C content. According to antiSMASH analysis, a total of 30 biosynthetic gene clusters (BGCs) were predicted to be involved in secondary metabolism, 12 of which were responsible for the production of polyketide- and non-ribosomal peptide-derived secondary metabolites. Gene cluster 5 was responsible for macrolide biosynthesis in a strain-specific 126,331-bp genomic island belonging to the left-arm region. Combined genomics-metabolomics analysis led to the discovery of three 22-membered macrolides (compounds 1-3). Their structures were elucidated by using spectroscopic techniques including high-resolution electrospray ionization mass spectroscopy (HRESIMS) and nuclear magnetic resonance (NMR). The absolute configurations of compounds 1-3 were determined by the X-ray single crystal diffraction and NMR data analysis. All three compounds displayed moderate cytotoxic activities toward tumor cell lines HepG2, A549, and HCT116.

MedicineQ4 · MEDICINE

Influences of different dose of tirofiban for acute ST elevation myocardial infarction patients underwent percutaneous coronary intervention

Q4 · MEDICINE

ArticleOA

Author: Feng, Meiqin ; Wang, Haixia

AbstractTirofiban is widely used in patients with acute ST elevation myocardial infarction (STEMI) underwent percutaneous coronary intervention (PCI). This drug can efficiently improve myocardial perfusion and cardiac function, but its dose still remains controversial. We here investigated the effects of different dose of tirofiban on myocardial reperfusion and heart function in patients with STEMI. A total of 312 STEMI patients who underwent PCI in our hospital from March 2017 to March 2018 were enrolled and randomly divided into control group (75 cases, 0 μg/kg), low-dose group (79 cases, 5 μg/kg), medium-dose group (81 cases, 10 μg/kg) and high-dose group (77 cases, 20 μg/kg). The infarction-targeted artery flow grade evaluated by thrombolysis in myocardial infarction (TIMI), corrected TIMI frame count (CTFC) and sum-ST-segment resolution were recorded. At Day 7 and Day 30 after PCI, the left ventricular ejection fraction (LVEF), left ventricular end diastolic diameter, left ventricular end systolic diameter, major adverse cardiovascular events and the hemorrhage and thrombocytopenia were also evaluated. After PCI, the rate of TIMI grade 3, CTFC and incidence of sum-ST-segment resolution > 50% of high-dose group were significantly higher than those of control group, low-dose group and medium-dose group (P < .05), and the CTFC of medium -dose group were significantly higher than that of control group, low-dose group (P < .05). Moreover, the LVEF, left ventricular end diastolic diameter and left ventricular end systolic diameter of high-dose group were significantly improved than those of other groups, and the LVEF of medium-dose group was significantly superior to that of low-dose group (P < .05). However, the incidence of major adverse cardiac events in high-dose group was significantly decreased, while the hemorrhage and incidence of thrombocytopenia of high-dose group were significantly higher than those of other 3 groups (P < .05). The tirofiban can effectively alleviate the myocardial ischemia-reperfusion injury and promote the recovery of cardiac function in STEMI patients underwent PCI. Although the high-dose can enhance the clinical effects, it also increased the hemorrhagic risk. Therefore, the rational dosage application of tirofiban become much indispensable in view of patient's conditions and hemorrhagic risk, and a medium dose of 10 μg/kg may be appropriate for patients without high hemorrhagic risk.

100 Deals associated with AstraZeneca (Wuxi) Trading Co. Ltd.

100 Translational Medicine associated with AstraZeneca (Wuxi) Trading Co. Ltd.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 19 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Zibotentan ( ETA )	Prostatic Cancer More	Discontinued

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

AstraZeneca (Wuxi) Trading Co. Ltd.

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 19 Nov 2024

Current Projects

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing